Descemetorhexis without grafting for fuchs endothelial dystrophy-supplementation with topical ripasudil

Cornea

Volumn 36, Issue 6, 2017, Pages 642-648

  Moloney, Gregory ^a,b   Petsoglou, Constantinos ^a,b   Ball, Matthew ^a,b   Kerdraon, Yves ^a,b   Höllhumer, Roland ^a   Spiteri, Natasha ^a   Beheregaray, Simone ^a   Hampson, Judith ^a   D'Souza, Mario ^b   Devasahayam, Raj N ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SYDNEY EYE HOSPITAL   (Australia)

^c Lions NSW Eye Bank   (Australia)

Author keywords

Descemetorhexis; Fuchs dystrophy; Ripasudil

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CHLORAMPHENICOL; DEXAMETHASONE; EYE DROPS; KETOROLAC; RHO KINASE INHIBITOR; RIPASUDIL; SODIUM CHLORIDE; ISOQUINOLINE DERIVATIVE; K-115; RHO KINASE; SULFONAMIDE;

ARTICLE; BEST CORRECTED VISUAL ACUITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL CORNEA DYSTROPHY; CORNEA SURGERY; CORNEAL CLEARANCE; DESCEMETORHEXIS; ENDOTHELIAL KERATOPLASTY; HUMAN; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; THERAPY EFFECT; TOPICAL TREATMENT; VISION; VISUAL SYSTEM PARAMETERS; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CELL COUNT; DESCEMET MEMBRANE; DESCEMET STRIPPING ENDOTHELIAL KERATOPLASTY; EYE REFRACTION; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; TOPICAL DRUG ADMINISTRATION; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ADULT; AGED; CELL COUNT; COMBINED MODALITY THERAPY; DESCEMET MEMBRANE; DESCEMET STRIPPING ENDOTHELIAL KERATOPLASTY; FEMALE; FOLLOW-UP STUDIES; FUCHS' ENDOTHELIAL DYSTROPHY; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; REFRACTION, OCULAR; RHO-ASSOCIATED KINASES; SULFONAMIDES; VISUAL ACUITY;

EID: 85017576770     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0000000000001209     Document Type: Article

References (20)

1. Moloney G, Chan UT, Hamilton A, et al. Descemetorhexis for Fuchs' dystrophy. Can J Ophthalmol. 2015;50:68-72.
2. Borkar D, Veldman P, Colby KA. Treatment of Fuchs endothelial dystrophy by Descemet stripping without endothelial keratoplasty. Cornea. 2016;35:1267-1273.
3. Ziaei M, Barsam A, Mearza AA. Spontaneous corneal clearance despite graft removal in Descemet stripping endothelial keratoplasty in Fuchs endothelial dystrophy. Cornea. 2013;32:e164-e166.
4. Dirisamer M, Ham L, Dapena I, et al. Descemet membrane endothelial transfer: "free-floating" donor Descemet implantation as a potential alternative to "keratoplasty". Cornea. 2012;31:194-197.
5. Shah RD, Randleman JB, Grossniklaus HE. Spontaneous corneal clearing after Descemet's stripping without endothelial replacement. Ophthalmology. 2012;119:256-260.
6. Lam FC, Bruinsma M, Melles G. Descemet membrane endothelial transfer. Curr Opin Ophthalmol. 2014;25:353-357.
7. Bleyen I, Saelens I, van Dooren B, et al. Spontaneous corneal clearing after Descemet's stripping. Ophthalmology. 2013;120:215.
8. Satué Palacián M, Sánchez Pérez A, Idoipe Corta M, et al. Descemetorrexis y aclaramiento corneal: una nueva perspectiva en el tratamiento de las enfermedades del endotelio [in Spanish]. Arch Soc Esp Oftalmol. 2014;89:1-3.
9. Nakagawa H, Koizumi N, Okumura N, et al. Morphological changes of human corneal endothelial cells after Rho-associated kinase inhibitor eye drop (ripasudil) administration: A prospective open-label clinical study. PLoS One 2015;10:e0136802.
10. Okumura N, Koizumi N, Ueno M, et al. Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops. Br J Ophthalmol. 2011;95:1006-1009.
11. Koizumi N, Okumura N, Ueno M, et al. Rho-associated kinase inhibitor eye drop treatment as a possible medical treatment for Fuchs corneal dystrophy. Cornea. 2013;32:1167-1170.
12. Okumura N, Koizumi N, Kay EP, et al. The ROCK inhibitor eye drop accelerates corneal endothelium wound healing. Invest Ophthalmol Vis Sci. 2013;54:2493-2502.
13. Koizumi N, Okumura N, Ueno M, et al. New therapeutic modality for corneal endothelial disease using Rho-associated kinase inhibitor eye drops. Cornea. 2014;33(suppl 11):S25-S31.
14. Okumura N, Inoue R, Okazaki Y, et al. Effect of the Rho kinase inhibitor Y-27632 on corneal endothelial wound healing. Invest Ophthalmol Vis Sci. 2015;56:6067-6074.
15. Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014;74: 2211-2215.
16. Okumura N, Okazaki Y, Inoue R, et al. Effect of the Rho-associated kinase inhibitor eye drop (ripasudil) on corneal endothelial wound healing. Invest Ophthalmol Vis Sci. 2016;57:1284-1292.
17. Galvis V, Tello A, Berrospi RD, et al. Descemetorhexis without endothelial graft in Fuchs dystrophy. Cornea. 2016;35:e26-e28.
18. Koenig SB. Planned Descemetorhexis without endothelial keratoplasty in eyes with Fuchs corneal endothelial dystrophy. Cornea. 2015;34:1149-1151.
19. Arbelaez JG, Price MO, Price FW, Jr. Long-term follow-up and complications of stripping Descemet membrane without placement of graft in eyes with Fuchs endothelial dystrophy. Cornea. 2014;33: 1295-1299.
20. Oie Y, Watanabe S, Nishida K. Evaluation of visual quality in patients with Fuchs endothelial corneal dystrophy. Cornea. 2016;35: S55-S58.